The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.
about
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individualsDose response of ACE inhibitors: implications of the SECURE trialNonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review.Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current statusRole of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyAttenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice.Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials.Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations.The therapeutic role of RAS blockade in chronic heart failure.The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease.Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease.ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease.Angiotensin-converting enzyme inhibitors and coronary heart disease prevention.Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.Perindopril: do randomised, controlled trials support an ACE inhibitor class effect? A meta-analysis of clinical trials.Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literatureBayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function.Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials.Blocking the renin-angiotensin system: dual- versus mono-therapy.Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care.Effectiveness of blood pressure lowering: evidence-based comparisons between men and women.Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction.Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials.Oxidative stress and early atherosclerosis: novel antioxidant treatment.Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis.Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence?Pharmacotherapy for hypertension in adults aged 18 to 59 years.Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.Quinapril decreases antifibrinolytic and prooxidative potential of propofol in arterial thrombosis in hypertensive rats.ACE inhibitors: back to prime time?Relation between blood pressure after an acute coronary event and subsequent cardiovascular risk.Different Angiotensin-converting enzyme inhibitors and the associations with overall and cause-specific mortalities in patients with hypertension.Modern treatment of patients at risk: still a HOPE for ACE inhibitors?New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study.
P2860
Q24186039-DB26FA7E-8D1A-46BF-853E-3CE9A9375B22Q24793271-6DFE0C22-3EB4-498E-BF11-F64BB5553CEFQ30583012-751EF4CF-B1A4-4822-8ECA-41E97DA052E5Q33300205-B67D34D9-2628-4E32-B395-9A08CA5275C7Q33504342-CA92F2C4-C102-4391-B7B8-3D5ECE4E1602Q34124779-63A7318D-A4A8-4427-9F7D-AB2FB32788CDQ34306932-59F1A8BA-E54B-44EC-99F7-25F9E8B03B42Q34386587-9B7D3EA1-1E10-4656-906B-2CEA49937DE1Q34530216-60814E15-27FE-4C37-996F-617EE5E1992DQ34549694-AD11C9CB-4C5B-45CB-A5A4-296DB09EAFB7Q34583579-DA7701D4-5AFC-4E20-A410-B8B6CA910C58Q34915602-F3A78C68-8637-4255-A2AB-78D3F65FD878Q35763822-101B8DA3-9F62-41F5-AA2F-068F2577A140Q35875450-3BFA3660-CC3E-434D-95E1-E562633AA98EQ36642656-0EB8CF22-DCE3-4E22-B810-F1D3B1BEBAB9Q36726341-1C4CF9A2-5948-4E59-A899-7E17FD53547CQ36814991-8F99EE69-E203-4CC3-AFAE-6AD710788963Q37012910-61B48FC3-B0DE-47C3-A790-3EE8AFF9DA18Q37041380-9B0E6E90-0439-403A-8CC1-336D3D1DA0EAQ37058920-06953E4F-C9A2-4F3A-A7BD-CEB26CE5B683Q37104532-F7D197E2-491E-4FAE-886A-9BF10AEE3533Q37292868-16278603-FA4E-40FD-A91F-080009644C65Q37511006-DD5E8046-DB14-471B-B901-CE70F4AEA9E7Q37679209-66992A5F-D20A-4FF3-B90E-542C017B2541Q37688159-D0D23AD7-6412-4AF9-9886-2C545996EC2CQ37846720-60EB1395-A282-46CC-941C-021D0CC50090Q37947405-93F9491D-2458-431E-8C3F-D3CDA7172415Q38128175-80AB703A-5F94-422D-B274-AD367DE16173Q38168840-A1D32BD8-1A93-4C3A-AF4B-2371854CCFD0Q38269619-0C14E982-99BC-4689-8632-D253C72236ADQ38317550-609E6C89-DE74-4D86-9D07-24EF9503F3F5Q38409909-8FB568F1-6A8B-405F-A7D2-7520124B3E57Q38622305-9AFF6956-5491-439B-B9E5-600371B36362Q40009748-95F24DB6-6B14-470C-973C-6671B0F01FCDQ41945916-0C4F29AA-F82C-41E1-AFEA-023356BB61F3Q42409973-F2A0C73F-C7DF-4C63-90E7-2192444534B3Q43015497-A756E973-D434-415E-BD7A-B8BDA494C319Q44263148-65A4BECA-6E82-4B68-8BF3-7154C6683B87Q44727959-DEDA29F6-9EDC-4865-992E-9308FA57C8AEQ44909422-351940A2-EDE6-4DFE-961D-7BA13F226586
P2860
The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
The QUinapril Ischemic Event T ...... ved left ventricular function.
@en
The QUinapril Ischemic Event Trial
@nl
type
label
The QUinapril Ischemic Event T ...... ved left ventricular function.
@en
The QUinapril Ischemic Event Trial
@nl
prefLabel
The QUinapril Ischemic Event T ...... ved left ventricular function.
@en
The QUinapril Ischemic Event Trial
@nl
P2093
P1476
The QUinapril Ischemic Event T ...... ved left ventricular function.
@en
P2093
A Uprichard
L Cashin-Hemphill
L Schwartz
QUIET Study Group
P304
P356
10.1016/S0002-9149(01)01461-8
P407
P577
2001-05-01T00:00:00Z